Hostname: page-component-848d4c4894-tn8tq Total loading time: 0 Render date: 2024-06-30T20:57:51.423Z Has data issue: false hasContentIssue false
  • English
  • Français

Decision making to discharge patients from airborne infection isolation rooms: The role of a single GeneXpert MTB/RIF strategy in Brazil

Published online by Cambridge University Press:  17 April 2020

Lucas José Bazzo Menon Open the ORCID record for Lucas José Bazzo Menon [Opens in a new window] ,
Cinara Silva Feliciano ,
Mateus Rennó de Campos  and
Valdes Roberto Bollela
Lucas José Bazzo Menon*
Affiliation:
Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo (FMRP-USP), Ribeirão Preto, São Paulo, Brazil
Cinara Silva Feliciano
Affiliation:
Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo (FMRP-USP), Ribeirão Preto, São Paulo, Brazil
Mateus Rennó de Campos
Affiliation:
Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo (FMRP-USP), Ribeirão Preto, São Paulo, Brazil
Valdes Roberto Bollela
Affiliation:
Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo (FMRP-USP), Ribeirão Preto, São Paulo, Brazil
*
Author for correspondence: Lucas José Bazzo Menon, E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

Tuberculosis (TB) transmission in healthcare facilities is still a concern in low-income countries, where airborne isolation rooms are scarce due to high costs. We evaluated the use of single GeneXpert MTB/RIF, the molecular Mycobacterium tuberculosis (MTB) DNA and resistance to rifampicin (RIF) test, as an accurate and faster alternative to the current criteria of 3 negative acid-fast bacilli (AFB) smears to remove patients from airborne isolation.

Methods:

In this real-world investigation, we evaluated the impact of a single GeneXpert MTB/RIF on the decision making for discharging patients from respiratory isolation. We enrolled patients with suspected pulmonary TB in a public hospital that provides care for high-complexity patients in Brazil. We studied the performance, costs, and time saved comparing the GeneXpert MTB/RIF with AFB smears.

Results:

We enrolled 644 patients in 3 groups based on the number of AFB smears performed (1, 2, and 3, respectively) on respiratory specimens. GeneXpert MTB/RIF demonstrated good performance compared to AFB smear to rule out TB in all groups. The negative predictive value for AFB smear was 94% (95% confidence interval [CI], 0.90–0.97) and 98% (95% CIs, 0.94–0.99) for GeneXpert MTB/RIF in G3. The isolation discharge based on 3 AFB smears took 84 hours compared to 24 hours with GeneXpert MTB/RIF, which represents 560 patient-days saved in the isolation rooms.

Conclusion:

A single GeneXpert MTB/RIF is a fast and strong predictor for TB absence in a high-complexity hospital, which is quite similar to results obtained in recent studies in low-burden settings. This molecular test may also increase patient rotation through isolation rooms, with a positive impact in the emergency room and infectious diseases wards.

Type
Original Article
Information
Infection Control & Hospital Epidemiology , Volume 41 , Issue 7 , July 2020 , pp. 784 - 788
Check for updates
Copyright
© 2020 by The Society for Healthcare Epidemiology of America. All rights reserved.

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Global tuberculosis report, 2018. World Health Organization website. https://apps.who.int/medicinedocs/en/m/abstract/Js23553en/. Published 2018. Accessed April 1, 2020.Google Scholar
Jensen, PA, Lambert, LA, Iademarco, MF, et al. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings. MMWR Recomm Rep 2005; 54(RR-17):1–141.Google ScholarPubMed
Centers for Disease Control and Prevention. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care facilities. MMWR Recomm Rep 1994;43 (RR-13):1–132.Google Scholar
Bates, JH. Diagnosis of tuberculosis. Chest 1979;76:757–763.CrossRefGoogle ScholarPubMed
Division of Microbiology Devices, Office of in Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health, Food and Drug Administration, Centers for Disease Control and Prevention (CDC). Revised device labeling for the Cepheid Xpert MTB/RIF assay for detecting Mycobacterium tuberculosis. Morb Mortal Wkly Rep 2015;64:193.Google Scholar
Hughes, R, Wonderling, D, Li, B, Higgins, B. The cost effectiveness of nucleic acid amplification techniques for the diagnosis of tuberculosis. Respir Med 2012;106:300–307.CrossRefGoogle Scholar
Marks, SM, Cronin, W, Venkatappa, T, et al. The health-system benefits and cost-effectiveness of using Mycobacterium tuberculosis direct nucleic acid amplification testing to diagnose tuberculosis disease in the United States. Clin Infect Dis 2013;57:532–542.CrossRefGoogle ScholarPubMed
Chaisson, LH, Roemer, M, Cantu, D, et al. Impact of GeneXpert MTB/RIF assay on triage of respiratory isolation rooms for inpatients with presumed tuberculosis: a hypothetical trial. Clin Infect Dis 2014;59:1353–1360.CrossRefGoogle ScholarPubMed
Lippincott, CK, Miller, MB, Popowitch, EB, et al. Xpert MTB/RIF assay shortens airborne isolation for hospitalized patients with presumptive tuberculosis in the United States. Clin Infect Dis 2014;59:186–92.CrossRefGoogle ScholarPubMed
Luetkemeyer, A, Firnhaber, C, Kendal, M, et al. Xpert MTB/RIF versus AFB smear to determine respiratory isolation of US TB suspect. Abstract number 824. Conference on Retroviruses and Opportunistic Infections (CROI), February 23–26, 2015, Seattle, WA.Google Scholar
Sulis, G, Agliati, A, Pinsi, G, et al. Xpert MTB/RIF as add-on test to microscopy in a low tuberculosis incidence setting. Eur Respir J 2018;51(3): pii: 1702345.CrossRefGoogle Scholar
Brasil Ministério da Saúde, Secretaria de Ciência, Tecnologia e Insumos Estratégicos. Portaria nº 48, de 10 de setembro de 2013. Torna pública a decisão de incorporar o Teste Xpert MTB/RIF para diagnóstico de casos novos de tuberculose e detecção de resistência à rifampicina no Sistema Único de Saúde—SUS, 2013.Google Scholar
Cowan, JF, Chandler, AS, Kracen, E, et al. Clinical impact and cost effectiveness of Xpert MTB/RIF testing in hospitalized patients with presumptive pulmonary tuberculosis in the United States. Clin Infect Dis 2017;64:482–489.Google ScholarPubMed
Poonawala, H, Leekha, S, Medina-Moreno, S, et al. Use of a single Xpert MTB/RIF assay to determine the duration of airborne isolation in hospitalized patients with suspected pulmonary tuberculosis. Infect Control Hosp Epidemiol 2018;39:590–595.CrossRefGoogle ScholarPubMed
Al-Darraji, HA, AbdRazak, H, Ng, KP, et al. The diagnostic performance of a single Gene Xpert MTB/RIF assay in an intensified tuberculosis case finding survey among HIV-infected prisoners in Malaysia. PLoS One 2013;8:e73717.CrossRefGoogle Scholar
Chaisson, LH, Duong, D, Cattamanchi, A, et al. Association of rapid molecular testing with duration of respiratory isolation for patients with possible tuberculosis in a US hospital. JAMA Intern Med 2018;178:1380–1388.CrossRefGoogle Scholar
Millman, AJ, Dowdy, DW, Miller, CR, et al. Rapid molecular testing for TB to guide respiratory isolation in the US: a cost-benefit analysis. PLoS One 2013;8:e79669.CrossRefGoogle Scholar
Aubry, A, Veziris, N. Smear microscopy complements Xpert MTB/RIF when considering nontuberculous mycobacterial infections. Am J Respir Crit Care Med 2019;200:1072–1073.CrossRefGoogle ScholarPubMed
Lee, HS, Kee, SJ, Shin, JH, et al. Xpert MTB/RIF Assay as a substitute for smear microscopy in an intermediate-burden setting. Am J Respir Crit Care Med 2019;199:784–794.CrossRefGoogle Scholar